SYN2BIO
Research SYN2BIO (S2B.WA) on Bullrun: market cap PLN 511.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerS2B.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 511.53M
- Financial periodFY2025
- RevenuePLN 0
- Net income-PLN 23.66M
- Free cash flow-PLN 21.09M
Valuation Snapshot
latest market cap is PLN 511.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 0 | -PLN 23.66M | -PLN 21.09M | n/a | n/a | PLN 7.22M | PLN 651.42K | PLN 16.68M |
| FY2024 | PLN 0 | -PLN 16.34M | -PLN 22.52M | n/a | -1.87 | PLN 7.06M | PLN 573.62K | PLN 18.85M |
| FY2023 | PLN 0 | -PLN 11.85M | -PLN 13.51M | n/a | -1.36 | PLN 5.98M | PLN 615.95K | PLN 11.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-06 | PLN 511.53M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About SYN2BIO
Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. It also engages in the research of new pharmaceutical compounds and its further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SYN2BIO's market cap?
SYN2BIO's market capitalization is PLN 511.53M.
What does SYN2BIO do?
Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. It also engages in the research of new pharmaceutical compounds and its further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.